Skip to main content

Market Overview

Chardan Upgrades Regeneron; Cites Fovista Failure, Stock's Recent Underperformance

Share:
Chardan Upgrades Regeneron; Cites Fovista Failure, Stock's Recent Underperformance

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has underperformed Amgen, Inc. (NASDAQ: AMGN) as well as the NBI year-to-date in 2016, while a key threat, in the form of Ophthotech Corp (NASDAQ: OPHT)'s Fovista, has been eliminated.

Chardan Capital’s Gbola Amusa upgraded the rating on Regeneron Pharma from Sell to Neutral, while raising the price target from $300 to $350.

Underperformance

Amusa mentioned that the stock has declined 23 percent since January 22, 2016, as compared to the 8 percent decline in Amgen shares and a 6 percent decline in Nasdaq Biotech.

“Although we continue to have caution on the potential for Praluent to be taken off the US market or for a substantial royalty to be paid from Regeneron and partner Sanofi SA (ADR) (NYSE: SNY) to Amgen, the recent underperformance of Regeneron suggests better market appreciation of Praluent patent risks,” the analyst stated.

Risk Eliminated

In addition, with the announced failure of Fovista, on December 12, in the pivotal Phase III trials in wet AMD, Amusa believes an important risk to Regenron’s Eylea franchise for the same ailment has been “neutralized”.

At Last Check

Latest Ratings for REGN

DateFirmActionFromTo
May 2021Morgan StanleyMaintainsEqual-Weight
May 2021SVB LeerinkMaintainsOutperform
Apr 2021Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

 

Related Articles (AMGN + REGN)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech News Upgrades Health Care Price Target Analyst Ratings Movers Best of Benzinga

Latest Ratings

StockFirmActionPT
NETIJefferiesMaintains22.0
ATUSB of A SecuritiesDowngrades38.0
CNIVertical ResearchUpgrades
LINVertical ResearchUpgrades330.0
SITEBerenbergUpgrades207.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com